We hope he does a better job than some of the playlists we’ve seen recently !
NeonMind Biosciences Inc. (CSE: NEON) (“NeonMind“) a company conducting research into the potentially therapeutic uses of compounds found in psychedelic mushrooms, is pleased to announce that it has added Frank Russo as an advisor and consultant to assist the Company in selecting or developing music playlists for its clinical trials or for use with treatments to support optimum mental health.
NeonMind Engages Music Expert Dr. Frank Russo
To view an enhanced version of this graphic, please visit:
Frank Russo is a professor of Psychology at Ryerson University. He is also an affiliate scientist at the Toronto Rehabilitation Institute, core member of the McMaster Institute for Music and the Mind (MIMM), and adjunct professor at the University of Toronto’s Music and Health Collaboratory (MaHRC). In his Science of Music Auditory Research and Technology (SMART) Lab at Ryerson, he conducts basic research on the biological, cognitive, and social-emotional bases of music and speech. His work tends to be interdisciplinary in nature but is most closely aligned with the academic disciplines of perceptual science, cognitive science, emotion science, and neuroplasticity. He is a Fellow of the Canadian Psychological Association and Massey College, and is a past president of the Canadian Acoustical Association.
He also engages in two related areas of applied research. The first area seeks to develop and optimize assistive and rehabilitative technologies that may support perception and production of vocal-facial emotion. The second area assesses the potential for music-based interventions to contribute to health and wellbeing.
“Dr. Russo is an expert working at the intersection of brain health, psychology and music,” said Penny White, CEO of NeonMind. “He will assist our team in examining the intersection between psychedelics and music, the neurological impact of both and related therapeutic implications.”
Dr. Russo will assist NeonMind in developing effective protocols for psychedelic treatments that incorporate music as part of the treatment in human clinical trials to be submitted for approval to Health Canada. He will also assist NeonMind in building alliances and partnerships in the music industry, and establish one or more multi-party projects to further develop data that can support the use of music to enhance mental health and treat drug addiction.
“I am excited to have the opportunity to work with NeonMind on exploring this groundbreaking area of cognitive science,” said Frank Russo. “Music has such a transformative effect on the brain, and I can foresee its potential to enhance the results that are achievable with psychedelic therapy as well.”